RSS | Print | PDF | Email Page


Product-by-Process Claims Invalid when the Process Does Not Impart Structural or Functional Differences, PTAB Litigation Blog

May 2017

Visit the Jones Day PTAB Litigation Blog.

The PTAB issued a final written decision in IPR2016-00006, holding claims 1–22 of U.S. Patent No. 8,497,393 ("the ’393 patent") unpatentable under 35 U.S.C. § 102(b) and 35 U.S.C. § 103(a). All of the claims are product-by-process claims to prostacyclin derivatives including treprostinil, the active ingredient in the pulmonary arterial hypertension drug Remodulin®.

Read the full article at


Areas of Concentration


United States